Wragge Lawrence Graham & Co
- Litigation / Dispute Resolution (78)
- Company/Commercial (30)
- Pharma/Biotech (21)
- In-House (16)
- Information Technology (13)
- Competition/EU (9)
- Corporate (9)
- Healthcare (9)
- Real Estate (9)
- Construction (6)
- Telecoms (6)
- Banking / Finance (5)
- Commodities (5)
- Employment (5)
- Funds (5)
- Media/Entertainment/Sport (5)
- Pensions (5)
- Environment (3)
- Planning (3)
- PPP/PFI/Commercial projects (3)
- Public Sector/Local Authority (3)
- Regulatory and compliance (3)
- Tax (3)
- Consumer/Retail (2)
- Crime (2)
- Energy (2)
- Personal tax / Trusts (2)
- Private Client (2)
- Private Equity (2)
- Business Tax (1)
- Clinical/Medical Negligence (1)
- Insolvency & restructuring (1)
- Insurance/reinsurance (1)
- Transport (Including aviation and shipping) (1)
Sort By: Newest first | Oldest first
Court finds EC’s decisions to grant marketing authorisations for two generic products were consistent with legal provision.
Skilled person would not have had a sufficient expectation that test outcome would be successful...
…and hopefully, guidance on ’fair and reaonable’ obligations too.
Guidance expected on fair, reasonable and non-discriminatory (FRAND) rate in standards-based industries...
The Government has launched a new consultation following the repeal of s52 of the Copyright Designs and Patents Act 1988.
There has long been a case for harmonisation of the law and now a draft Bill has been published with the aim of doing so.
The signatory states to the UPC Agreement have agreed a Protocol which paves the way, in terms of practical steps, to getting the Unified Patent Court up and ready to run.
YSL obtained its registrations in 2006. H&M sought to invalidate the registrations on the basis that they lacked the necessary individual character in light of its earlier ‘Fantastic Shopper’ design.
The CJEU’S answer to Nestlé’s application to register a shape mark for its four-finger chocolate bar is a classic lawyer’s answer: ‘it depends’. But depends on what?
Also: forms of protection; enforcement of rights; and more.
The European Parliament has published a revised form of a report that proposed changes to copyright law in the EU.
…but court stays injunctive relief.
Useful guidance on the “obvious to try” doctrine as Dovobet patent is judged valid in CoA.
Good news for those selling copies of iconic works as proposed repeal is put on back burner;...
Welcome decision redresses the previous imbalance between patentee and prospective licensee.
Community trademarks: what is the territorial extent of the requirement for use and acquired distinctiveness?
Two recent decisions of the Intellectual Property Enterprise Court have raised interesting questions about the territorial requirements for use of CTMs by the proprietor.
The US Supreme Court was invited to overturn Brulotte, which would have aligned its licensing law with Europe. It failed to do so.
Wragges joins forces with Gowlings to launch new international law firm.
Hospira v Genentech III: Swiss form claim obvious in view of paper reporting the existence of Phase III trial
Arnold J has delivered the latest blow in the ongoing saga surrounding trastuzumab (the monoclonal antibody in Herceptin) and Hospira’s continued efforts to knock out Genentech’s patents.
In a dispute between Smith & Nephew and ConvaTech, the CoA has ruled that “between 1 per cent and 25 per cent” extends to all values = 0.5 per cent and <25.5 per cent.